MedTrace Logo

Sepsis-Associated Purpura Fulminans International Registry - Europe

NCT02238795 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2025-05-21

Study results available
· View outcomes & findings →

Summary

Sepsis-associated Purpura fulminans (SAPF) is a rare life-threatening condition. It is characterized by multiple skin lesions which rapidly progress to necrosis and gangrene. SAPF is a manifestation of widespread clot formation in small blood vessels which emerges secondarily to severe bacterial and viral infections. The clinical presentation of SAPF is dominated by symptoms of severe sepsis and multiple organ failure which are further aggravated by the massive skin lesions.

At present, there are no evidence-based guidelines for the medical management of SAPF. With numerous therapeutic approaches in use, there are no consistent comparisons of their efficacy. Altered role of causal pathogens following the introduction of meningococcal and pneumococcal prophylactic vaccines also remains to be investigated.

The goal of the registry is comprehensive collection and evaluation of information concerning the epidemiology, morbidity, therapy and outcome of SAPF.

Conditions

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • University Hospital Tuebingen

    collaborator OTHER

  • University Hospital of Cologne

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Hannover Medical School

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Evangelisches Krankenhaus Bielefeld gGmbH

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Frank M Brunkhorst, MD · Center for Clinical Studies, Jena University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238795 on ClinicalTrials.gov